Fig 2.

Patients who achieved an erythroid response by 13 and 53/55 weeks. A major erythroid response was defined as: i) an increase in Hb concentration of ≥20 g/l from baseline or ii) transfusion-independent for patients who were transfusion-dependent at screening. A minor erythroid response was defined as: i) an increase in Hb concentration of ≥10 and <20 g/l from baseline or ii) ≥50% decrease in transfusion requirements for patients who were transfusion-dependent at screening. (A) Percentage of patients achieving an erythroid response after 13 weeks of darbepoetin alfa therapy (the primary end-point). (B) The percentage of patients with an erythroid response after 53/55 weeks of darbepoetin alfa therapy. Error bars indicate the upper 95% CL. ESA, erythropoiesis-stimulating agent; CL, confidence limit.